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Abstract Activation-induced cytidine deaminase (AID) is a DNA editing protein that plays an
essential role in threemajor events of immunoglobulin (Ig) diversification: somatic hypermutation,
class switch recombination and Ig gene conversion. Mutations in the AID gene (AICDA) have been
found in patients with autosomal recessive Hyper-IgM (HIGM) syndrome type 2. Here, two 9- and
14-year-old Brazilian sisters, from a consanguineous family, were diagnosed with HIGM2 syndrome.
Sequencing analysis of the exons from AICDA revealed that both patients are homozygous for a
single C to G transversion in the third position of codon 15, which replaces a conserved
Phenylalanine with a Leucine. To our knowledge, this is a new AICDA mutation found in HIGM2
patients. Functional studies confirm that the homologous murine mutation leads to a dysfunctional
protein with diminished intrinsic cytidine deaminase activity and is unable to rescue CSR when
introduced in Aicda−/−stimulated murine B cells. We briefly discuss the relevance of AICDA
mutations found in patients for the biology of this molecule.
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Hyper IgM (HIGM) syndrome is an immunodeficiency in which
patients show low or absent levels of IgG, IgA and IgE,
although presenting high values of IgM [1]. Patients with
HIGM are susceptible to recurrent infections and may also
show lymphoid hyperplasia, as well as autoimmune and
inflammatory disorders. The diagnosis is made through
laboratorial and clinical assessment. This syndrome may be
caused by X-linked or by autosomal recessive and occasion-
ally dominant mutations. The central defect is the inability
that B cells have to undergo class switch recombination
(CSR), and somatic hypermutation (SHM) is also frequently
compromised. During CSR, the original constant region of
the heavy chain, that forms the IgM antibody, is replaced by
downstream regions encoding the constant regions of the
heavy chain from the additional isotypes, IgGs, IgA or IgE,
each with unique effector functions [2]. In contrast, during
SHM it is the V(D)J region of the immunoglobulin genes that
is edited, mostly through the introduction of point mutations
that will allow the selection of high-affinity antibodies in the
context of the germinal center reaction [3].
B cells need to be activated through ligand–receptor
interactions in order to undergo CSR and SHM, which explains
i) the X-linked form of HIGM (HIGM1), caused by mutations in
the CD40L, a ligand that is normally transiently expressed on
activated helper T cells, [4–8]; ii) the autosomal recessive
HIGM3, caused by mutations in the CD40, a receptor constitu-
tively expressed by B cells [9]; and iii) mutations in the nuclear
factor κB (NF-κB) essential modulator gene (NEMO), that
interferes with the NF-κB signaling triggered by the CD40
cross-linking [10–12]. Since CSR involves the processing of DNA
lesions in the switch regions, the reaction depends on several
enzymes, including uracil-DNA glycosylase (HIGM5), which has
also been associated with HIGM [13]. The molecular charac-
terization of the phenotype of HIGM patients lacking mutations
in the documented candidate genes suggests that mutations in
other genes encoding repair molecules or survival factors are
likely to be associated with HIGM (HIGM4) in the future [14].
One last example of a gene that has been associated with
HIGM is AICDA. Mutations in this gene origin HIGM2 [15], now
also named B-cell intrinsic immunoglobulin class switch
recombination (Ig-CSR) deficiency 1 [16], which is charac-
terized by high levels of IgM, reduced or absent IgG, IgA and
IgE, and lymphoid hyperplasia. AICDA encodes the protein
activation-induced cytidine deaminase (AID), a DNA editing
enzyme expressed by B cells that deaminates cytosines from
exposed single-strands of DNA, which are the essential
triggering lesions for both CSR and SHM [15,17,18]. Thus,
the absent or low serum IgG, IgE and IgA in these patients
can be explained by the intrinsic inability of activated B cells
to undergo class switch recombination.
AID is a 198-residue protein with a molecular mass of
approximately 24 kDa that shares homology with Apolipopro-
tein B (apoB) mRNA-editing cytidine deaminase 1 (APOBEC-1)
[17]. AICDA mutants isolated from HIGM2 patients [15,19],
combined with functional analyses, have revealed a cytidine
deaminase domain, regions important for the shuttling
of AID between the nucleus and the cytoplasm, regions that
are specifically required for SHM or CSR and residues involved
in important post-translational modifications (reviewed
in [20]).In this article we describe AID F15L, a new recessive
mutation found in two Brazilian sisters with HIGM2, whose
parents are first-degree cousins. To unravel the functional
implications of this mutant form of AID, we performed a
functional analysis of the corresponding murine AID mutant
and found it to be impaired in deaminase activity and in its
ability to perform CSR. We complement the description of
these findings with a brief comment on the relevance of the
mutations found in patients to the biology of AID.
2. Patients
At the Children's Hospital, Faculdade de Medicina da
Universidade de São Paulo, Brazil, two 9 and 14-year-old
Brazilian sisters from a consanguineous family were diagnosed
with Hyper IgM syndrome 2 (HIGM2): low serum IgG and IgA
(≤2 standard deviation [SD] below normal values for age),
normal or elevated IgM and recurrent or severe bacterial
infections. Informed consent was obtained from both patients,
and bloodwas collected under institutional guidelines [21–23].
One of the sisters presented a more severe clinical picture
with pneumonia and meningitis, causing her deafness at the
age of 4 years. This patient presented hyperplasia of the
tonsils, bilateral cervical lymphadenopathy and bronchiecta-
sis. Laboratorial results showed serum IgM levels of 1.5 mg/ml
while the other immunoglobulins were all undetectable. The
other sister presented mostly respiratory manifestations and
was admitted to the intensive care unit oncewithHaemophilus
influenza, isolated from respiratory secretions, and had two
episodes of dental abscess. Her level of serum IgM was
2 mg/ml, while IgA and IgE were undetectable and IgG was
very low (0.4 mg/ml). At a physical exam, she presented
generalized lymphadenopathy and splenomegaly. Flow cy-
tometric analysis indicated normal lymphocyte count in both
patients, although the B cell counts were close to the lower
limit of the normal range.
3. Methods
3.1. Detection of serum immunoglobulins
The levels of serum immunoglobulins were detected as
previously described [24].
3.2. AICDA sequencing
The genomic sequence used to design the primers and
align the amplicons was NCBI NT_009714.17. For mapping
the exons and introns, we used the cDNA sequence from
NM_020661.2. After genomic DNA isolation from whole
blood, the five exons of AICDA were amplified by Polymer-
ase Chain Reaction (PCR) using a PTC-100 Programmable
Thermal Cycler (MJ Research Inc.), a Taq DNA polymerase
(Fermentas, USA) and specific primers, designed to flank
each of the five exons. PCR specific primers used to am-
plify and sequence the AICDA gene were the following:
exon 1: sense 5′GAACCATCATTAATTGAAGTGAG-3′ and
anti-sense 5′-ACGCCTCCCTAGGAAAGTGTGTC-3′; exon 2:
sense 5′-TGATGAGTATCTCTCAATTGGCC-3′ and anti-sense
5′-TCAGCATCTAGAAGACAGTGG-3′; exon 3 and 4: sense
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AGAGTGATTGAACAATAAG-3′; and exon 5: sense 5′-ACTCAGT
TTAGAAGACTCTCCGG-3′ and anti-sense 5′-ACCACTGTTA
ACTCAAATGAATC-3′. The PCR program was: 94 °C for 5 min,
35 cycles of 94 °C for 30 s, 56 °C for 30 s and 68 °C for
1.5 min; and one cycle of 68 °C for 7 min. Due to their
proximity, the third and the fourth exons were amplified and
sequenced as a single amplicon.
The PCR products were separated by gel electrophoresis,
treated with a QIAquick® PCR Purification Kit (QIAGEN) and
sequenced with a Big Dye Terminator Cycle Sequencing Kit
and analyzed with a 310 Genetic Analyzer ABI PRISM (Applied
Biosystems, Foster City, CA, USA), using the same primers as
before.
Sequences were first obtained straight from the PCR
products and were then confirmed from cloned PCR products,
using pGEM®-T Easy Vector Systems (Promega, Madison, WI).
3.3. Constructs and plasmids
We generated the murine AIDF15L in pASK by DpnI site-
directed mutagenesis of a previously cloned murine AID wild
type sequence [25], using the oligonucleotides 5′-TTCTTTAC
CAATTTGAAAAATGTCCGCT-3′ (the substitution is underlined)
and 5′-AGCGGACATTTTTCAAATTGGTAAAGAA-3′. The PCR
program used was 95 °C for 30 s, 18 cycles of 95 °C for 30 s;
55 °C for 30 s; and 68 °C for 2 min/kb of plasmid length. The
introduction of the mutation was then confirmed by sequenc-
ing. A pMX-AIDF15L construct was produced by cloning the
AIDF15L with a Kozac site PCR product into the pMX vector
using the BamHI and NotI restriction sites [26]. A set of murine
AID and murine AIDF15L constructs with linker-3 × FLAG
(-GGG-DYKDHDGDYKDHDIDYKDDDDK) fused to the C terminus
was also produced by PCR and cloned in pMX. For the
subcellular localization experiments, constructs encoding
the wild type and AIDF15L murine open reading frame fused
to the amino terminus of GFP were produced by DpnI site-
directed mutagenesis from an AID-GFP fusion in pQCXIP
(CLONTECH Laboratories, Inc.), a gift from Dr. Kevin McBride
[27].
3.4. Cytidine deaminase assay in Escherichia coli
AID, AIDF15L and pASK (empty vector) were each transformed
into a BH156 Uracil-DNA Glycosylase (UDG) deficient E. coli
strain. The cytidine deaminase activity assay was performed
essentially as described before [26,28]. Briefly, cultures from
individual colonies were grown overnight in 50 μg/ml of
ampicillin (Amp), 34 μg/ml of chloramphenicol (Cam) and
100 μg/ml of spectinomycin (Spc), with no agitation and then
used to inoculate cultures that were grown to log phase before
induction for 3 h with 0.2 μg/ml Anhydrotetracycline (Sigma)
to express AID, and with 1 mM Isopropylthiogalactoside (IPTG,
Promega), to express a kanamycin resistance gene with a
premature stop codon. The cultures were then plated at
appropriate dilutions in plates with Amp, Cam and Spc to
count live cells and in plates with Amp, Cam, Spc, IPTG and
kanamycin (60 μg/ml) to count cells that reverted the
premature stop codon. Mutation frequencies were measured
by determination of the average frequency of colonies
resistant to kanamycin within viable cells.3.5. CSR assay on transduced B cells
BOSC23 retroviral packaging cell line was propagated in
complete DMEM (supplemented with 10% Fetal Bovine
Serum, 1% Sodium Pyruvate and 1% Penicillin/Streptavidin),
at 37 °C, with 5% CO2. For transfection, 4 × 105 cells were
seeded in six-well plates and grown to 50–70% confluence.
Cells were co-transfected by the Ca-phosphate method with
an ecotropic helper plasmid pCL-Eco (Clontech) and retroviral
vectors (pMX) that express the murine AID, the AIDF15L
mutant protein or no protein at all (empty vector). These
experiments were also performed with the 3 × FLAG versions
of these constructs. Transfected cells were incubated in
complete DMEM for 36–48 h at 37 °C in a 5% CO2 incubator.
Mouse splenic B cells from 2 to 5-month old C57Bl/6J
Aicda−/−micewere isolated and separated by anti-mouse CD43
(Ly-48) beads (Myltenyi Biotech). 1 × 106 mouse splenic B cells
were stimulated throughout the duration of the assay with LPS
(20–25 μg/ml) and IL-4 (produced by the cell line X63) and
cultured in RPMI complete medium (10% Fetal Bovine Serum,
1% Sodium Pyruvate, 1% Penicillin/Streptavidin and 50 μM
β-Mercaptoethanol) for 24 h at 37 °C in a 5% CO2 incubator.
After 24 h in culture, the cells were transducedwith retroviral
supernatants and centrifuged for 1 h and 30min at 2500 rpm in
the presence of 10 μg/ml polybrene and 20 mM Hepes. The
medium was changed 12 h post-transduction and at day 3 the
cells were stained for IgG1. The GFP signal indicates that the
cells are expressing the genes encoded by the retrovirus.
3.6. Flow cytometry
Mouse splenic B cells were stained with an anti-mouse
IgG1-APC antibody (BD Biosciences Pharmingen). Dead cells
were excluded from the analysis on the basis of forward side
scatter and Propidium Iodide (PI, Invitrogen) gating. Cells
were acquired for GFP and surface IgG1 expression by
FACSCalibur and analyzed with FlowJo software (Tree Star).
3.7. Western Blot
Protein extraction was performed on CH12F3 cells [29]
transduced with pMX plasmids using an NP40 Cell Lysis Buffer
(Invitrogen, USA) supplemented with a protease inhibitor
cocktail (Complete, Roche, USA). Samples were run on a 4–
12% SDS-PAGE gel using the NuPAGE system (Life technolo-
gies, USA) and semi-dry transferred to Imobilon-P membrane
(Millipore). Membranes were blocked in 5% Bovine Serum
Albumin (BSA, Sigma, USA) in Tris-Buffered Saline 0.05%
Tween-20 (TBS-T), incubated with Anti-FLAG M2 (F-1804,
Sigma-Aldrich) for detection of AID-3 × FLAG proteins and
anti-GFP (ab6556, Abcam) for loading control. Blots were
developed using secondary antibodies conjugated to IR Dye
680 or 800 and imaged and quantified on a LiCor Biosciences
Odyssey near-infrared imaging platform. Signal was quanti-
fied in Odyssey (Li-Cor, Biosciences).
3.8. Microscopy
293T cells were plated on glass coverslips, transfected with
pQCXIP AID-GFP (the Venus variant), pQCXIP AIDF15L-GFP
or pQCXIP-GFP and evaluated 32–54 h post-transfection.
Figure 1 Mutation found in AICDA. A) Control's (top) and patients' (bottom) sequences showing a single non-silencing C to G
transversion in the third position of codon 15 (F15L) in AICDA that replaces a conserved Phenylalanine with a Leucine. B) Clustal sequence
alignment of the N-terminus of orthologous AID sequences from the following species (accession number): Homo sapiens (GenBank
AAP36918.1), Pan troglodytes (NP_001065277.1), Rattus norvegicus (NP_001094249.1), Mus musculus (NP_033775.1), Oryctolagus
cuniculus (GenBank AAX99151.1), Canis lupus (NP_001003380.1), Bos Taurus (NP_001033771.1), Gallus gallus (NP_001230151.1), Anolis
carolinensis (XP_003216895.1), Xenopus laevis (NP_001089181.1), Pleurodeles waltl (GenBank: CBG76578.2), Takifugu rubripes
(XP_003966295.1), Danio rerio (NP_001008403.1), and Ictalurus punctatus (NP_001187114.1). The arrow shows the position of the
mutation. C) E. coli cytidine deaminase assay tomeasure the intrinsic deaminase activity of themurine AID and AIDF15L. The plotted data
are from three independent experiments and the circles correspond to individual cultures. Mean and standard deviations for each
experiment are shown. D) Aicda−/−murine splenic B cells were stimulated with LPS and IL4, transduced with retroviruses expressing the
murine AID, AIDF15L or only the GFP reporter (vector), and at day 3 post-transduction the cells were stained for IgG1. The histograms show
the percentage of switching to IgG1 within the transduced (GFP+) live cells of one representative experiment.
Figure 2 AIDF15L expression levels, subcellular localization and the collection of AICDAmutations found in patients with HIGM2. A)
Western blot of protein extracts from CH12F3 cells transduced with pMX expressing plasmids encoding AID-3 × FLAG,
AIDF15L-3 × FLAG or pMX vector. The expression of AIDF15L is 22-32% of the wild-type level. B) Microscopic fields of 293T cells
transfected with plasmids encoding AID-GFP, AIDF15L-GFP or GFP (in green). DNA is visualized with Hoechst stain (in blue). C)
Percentage of cells showing a subcellular localization of the GFP signal in the cytoplasm and nucleus (C + N) or exclusively in the
cytoplasm (C); 140 to 615 cells were scored per condition. D) Mutations in AICDA. The genomic structure of the AICDA locus is shown
with introns as lines and exons as rectangles. The broken lines connect exons to the translated open reading frame of AICDA. The
complete collection of mutations found in AID patients is shown below the scheme of the molecule. These were found in homozygous
or compound heterozygous patients (except R190X, which comes from a heterozygous patient), and include missense mutations,
premature stop codons due to point mutations or to frame shifts resulting from insertions or deletions, deletions and mutations that
interfere with the proper splicing of the RNA [19,37,42,45–54]. A small selection of some mutations in conserved residues identified
in the context of basic research is also displayed above the molecule, including: S38A, which showed the importance of the
phosphorylation of residue S38 for the activity of AID [55,56]; T82I and the combination of K10E-E156G-T82I, which showed that minor
changes can produce AID mutants with enhanced mutagenic activity [43]; L189X, which showed that, of the AID-dependent DNA
editing reactions, the C-terminus is only required for CSR [26,37].
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283A Novel AID MutationLeptomycin B at 10 nM or 0.1% ethanol (vehicle control)
were added to cultures 1 to 3 h before fixation. Cells were
fixed in 4% formaldehyde in PBS. Nuclei were stained with
Hoechst (33342, Invitrogen). Preparations were analyzed on
a Leica SP5 confocal microscope. Images were processed
with LAS AF Lite software (Leica).4. Results and discussion
Preliminary direct sequencing analysis of the amplified
exons from AICDA revealed that the two patients have asingle non-silencing C to G transversion in the third position
of codon 15 (F15L), which replaces a Phenylalanine with a
Leucine. As can be observed in the chromatogram, at that
position there is a single peak (Fig. 1A), which indicates that
the mutation is homozygous in both patients. Cloning and
sequencing of the PCR products confirmed that both patients
are homozygous for the same mutation, as all PCR-derived
clones showed the same mutation. No other mutation was
detected in the sequences encoding the open reading frame
of AICDA. The patients live in the northeast area of Brazil,
where the population has a unique mixed ethnic background
of Portuguese, African (mainly from the Central Western
284 N. Caratão et al.Atlantic coast) and native Indian descents, who have been
merging since the 16th century [30]. To our knowledge,
this is the first description of the F15L AID mutation in
HIGM2 patients. A sequence alignment of the N-terminus of
AID from several species shows that F15 is highly conserved,
the amino acid being shared from reptiles to mammals;
furthermore, from sharks to amphibians the residue at that
position is a Tyrosine, which shares with Phenyalanine a
hydrophobic side chain (Fig. 1B).
As the human and murine AID molecules are 198-residue
highly conserved proteins that share 92.4% identity at the
amino acid level, in order to test whether this mutation is
sufficient to decrease AID activity and explain the HIGM2
syndrome of the two patients, we introduced the F15L
mutation in the AICDA gene, in plasmids encoding the murine
AID that we routinely use in our assays. We first tested the
intrinsic cytidine deaminase activity of the AIDF15L using an E.
coli-based assay that measures the ability of the expressed
molecules to revert through cytidine deamination a premature
stop codon in the gene that confers resistance to kanamycin,
thus restoring the capacity of the bacteria to grow in the
presence of the antibiotic. As can be observed in Fig. 1C, in
three independent experiments AIDF15L showed a drastic
decrease in activity compared to AID, but it nevertheless
consistently kept some residual activity when compared to the
empty vector, a result that is compatible with a recent
biochemical analysis of an identical mutation of unknown
origin [31]. We next investigated whether the AIDF15L form
was still able to induce CSR. We used retroviruses to express
AIDF15L in C57Bl/6J Aicda−/−mouse B cells stimulated with
IL-4 and LPS. Transduced B cells were identified by GFP
expression and the efficiency of CSR was determined by cell
surface IgG1 expression. The percentages of class switch
within the GFP+ cells were 22.3 for wild-type AID, 0.17 for
AIDF15L and 0.13 for the empty vector, indicating that the
AIDF15L has no activity, since it is comparable to the
background level (Fig. 1D). Similar experiments performed
with the 3 × FLAG versions of the molecule confirmed these
results (data not shown). These are short-term assays, which
may not detect the residual activity of AIDF15L observed in the
E. coli assay. Alternatively, it is possible that the stability of
the molecule in eukaryotic cells is diminished and/or that
additional functions required for CSR are compromised. Thus,
we first looked at the expression levels of AID in the
transduced cells of the lymphoma cell line CH12F3. AIDF15L
is clearly detected although it is less stable than AID, as it
tends to happen with several AID mutants (Fig. 2A). Keeping in
mind that the levels of AID expressed from the retroviruses are
higher than the physiological levels, the slight decrease in
stability does not explain the complete failure to rescue CSR
(Fig. 1D). We next looked at the subcellular location of AID
versus AIDF15L using fusions of these molecules to GFP. As
expected, while GFP is evenly distributed in the cytoplasm and
nucleus, the bulk of AID-GFP is found in the cytoplasm [27,32].
Under these conditions, we did not detect any major dif-
ference between the subcellular localization of AID-GFP and
AIDF15L-GFP (Fig. 2B). Since AID is actively excluded from the
nucleus by an exportin CRM1-dependent pathway, due to the
presence of a nuclear export signal in its carboxyl terminus
[27], it is possible to disturb the subcellular localization of the
molecule with leptomycin B (LMB), a CRM1 exportin inhibitor.
After 3 h of incubation with LMB, the GFP subcellularlocalization was not changed, but an increase in the nuclear
localization was observed in both AID-GFP and AIDF15L-GFP
(Figs. 2B and 2C). The F15L mutation is in a region that has
been characterized as a nuclear import signal [33], although it
is not one of the assigned critical residues. Furthermore, there
has been some controversy over the existence or nature of the
N-terminal NLS of AID [27,34,35]. In any case, we found no
evidence that the subcellular localization of AIDF15L could
contribute to its CSR phenotype. It should be kept in mind that
one of the patients had low but detectable serum IgG levels,
which is consistent with a residual cytidine deaminase activity
of AIDF15L that, although undetectable in our CSR assay, could
occur in vivo in a few cells that may then further expand and
partially compensate for the diminished AID activity.
AIDF15L is one of over 40 different mutations in the coding
region of AICDA that have been identified in HIGM2 patients
(Fig. 2D). In the seminal work of Revy et al. the study of these
mutationswas decisive to firmly establish AID as themain player
in both CSR and SHM [15]. The position of some mutations is
relatively trivial to explain. For instance, H56Y and C87R flank
and make part of a group of mutations that are predicted to
affect the catalytic site of the molecule, which must have an
intact Zn(2+) coordination and nucleotide binding to the
deaminated base. The changes introduced bymutations located
elsewhere in the molecule are less obvious, because the
structure of the AID protein has not been solved. Several
mutations located outside of the catalytic site, such as F15L, are
also known to decrease the intrinsic deaminase activity of the
molecule and attempts have been made to relate the effects to
loss of structural integrity or compromised interaction with the
substrate [31,36]. Interestingly, AID formswithmutations in the
N-terminus were shown to be competent for CSR but not SHM,
whereas AID forms with mutations in the C-terminus are able to
drive SHM but not CSR [37,38]. This led to the proposal that AID
is interacting with SHM-specific and CSR-specific factors
[26,37,38]. While no progress has been made to identify the
former, there is some evidence that the CSR-specific factor(s)
interacting with AID belong to the DNA repair pathways
recruited after the introduction of the lesions by the cytidine
deaminase [39–41], although the identity of the molecule(s)
directly interacting with AID in the context of this reaction
remains to be elucidated.
AID mutants from HIGM2 patients are necessarily null forms
or hypomorphs. These are typically homozygous, although
several examples of compound heterozygosity have been
reported, as well as a single case of a heterozygous mutation
that seems to encode a dominant negative form [42], which
is consistent with the hypothesis that AID acts as a dimer
or a tetramer. As our knowledge of AID and the collection
of AID mutants from patients increase, the chances of
finding interesting null or hypomorphic mutants associated
with HIGM2 decreases. In turn, it may be promising to
explore the possibility of discovering AID mutants with
enhanced or deregulated activity. In vitro work has shown
that very few mutations are required to drastically boost
the activity of AID [43] and the molecular signature of AID
activity has been found in a number of human lymphomas
[44]. Thus, although the sequencing of AICDA yielded no
results [44], it is possible that the failure to find AID mutants
associated with lymphomas and other tumors is due to a
limited number of patients sequenced so far for the AICDA
gene.
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